List of Clinical Trials

Bladder Cancer - C5701009

A Phase 3, Open-Label, Randromized Study To Evaluate Enfortumab Vedotin In Combination with Pembrolizumab in Adult Participants with Muscle Invasive Bladder Cancer who are Ineligible for or have Elected Not to Undergo Cystectomy

Breast Cancer - FLEX Registry

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

Breast Cancer - GLSI-21-01

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy

Breast Cancer - GS-US-595-6184

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Breast Cancer - JZP598-303

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab Deruxtecan treatment

Breast Cancer - OP-1250-302

USONR 25113/SCRI BRE 474 A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02) OP-1250-302 (Srivastava)

Colorectal - M24-533

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/​Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC)

Colorectal - C6461003

An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Bevacizumab in Combination with Chemotherapy in Treatment-Naïve Participants with Metastatic Colorectal Cancer

Colorectal - M24-560

An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Gastric, Gastroesophageal Junction (GEJ), and Esophageal - C6461016

A Phase 2/3 Interventional Study of PF-08634404 in Combination with Chemotherapy in Treatment Naive Participants with Locally Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma (C6461016)

Graft vs. Host Disease - DCC-3014-02-001

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy (DCC-3014-02-001)

Gynecological - INCB123667-203

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (INCB123667-203)

Gynecological - J5E-MC-JZXB

A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer (J5E-MC-JZXB) (FRAmework-01)

Gynecological - TREVI-OC-01

A Randomised, Open label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα low Expressing High grade Platinum Resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01) (D8991C00001)

Chronic Lymphocytic Leukemia - CLL-RR1

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia - NX-5948-201

NX-5948-201: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - J2N-MC-JZ03

Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-20020 with BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Non-Small Cell Lung Cancer - 849-007

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Non-Small Cell Lung Cancer - J3M-MC-JZQB

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

Non-Small Cell Lung Cancer - C5851005

A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer

Non-Small Cell Lung Cancer - C6461001

An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Pembrolizumab in Combination with Chemotherapy in Adult Participants withLocally Advance or Metastatic Non-Small Cell Lung Cancer

Small Cell Lung Cancer - ONC-005

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer - PUMA-ALI-4201

A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer

Small Cell Lung Cancer - CA245-0001

A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer - M23-384

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) (M23-384) (Ward)

Diffuse Large B-Cell Lymphoma - ALLO-501A-202

A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma

Previous CAR-T Cell Therapy - GC-LTFU-001

Long-term follow-up protocol for subjects treated with gene-modified T-cells

Previous BTKi LOSO-BTK-20020 Therpy - J2N-MC-JZ03

Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-20020 with BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Multiple Myeloma - 64007957MMY3005

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma - CA088-1000

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma

Multiple Myeloma - CB-011/caMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Multiple Myeloma - C1071032

USON 23254/SCRI MM 186 - A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone, or Pomalidomide, Bortezomib, Dexamethasone, or Carfilzomib, Dexamethasone, in Participants with Relapsed/Refractory Multiple Myeloma Who receive ed Prior Anti-CD38 Directed Therapy

Multiple Myeloma - 64007957MMY2010

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients

Metastatic Prostate Cancer - BNT32403

A Phase III, randomized, open-label trial of BNT324 versus docetaxel with prednisone/prednisolone in metastatic castration-resistant prostate cancer

HER2 Positive - FT825-101

A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors

BRAF V600E - CDRB436IIC01

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Solid Tumors - ART0380C001

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors